The latest biotech news

News and Trends 6 Jul 2023

LIfT produces neutrophil-based cell therapy from iPSCs

LIfT BioSciences has announced successful proof-of-concept production of its patented cancer-killing alpha neutrophils from induced pluripotent stem cells (iPSCs). The proof-of-concept using iN-LIfT, the company’s second-generation platform, which is derived from iPSCs (a type of cell that has been reprogrammed so it is capable of becoming any type of cell) has shown that the alpha […]

July 6, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 6 Jul 2023

Positive data from Sensorion hearing loss study

Sensorion, which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, has reported further analysis from its Proof of Concept (POC) phase 2a clinical trial of SENS-401 for residual hearing preservation in adult patients following cochlear implantation. In June 19, Sensorion announced that in preliminary […]

July 6, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 6 Jul 2023

AstraZeneca non-small cell lung cancer drug meets primary endpoint

Positive high-level results from AstraZeneca’s TROPION-Lung01 phase III trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant improvement for the dual primary endpoint of progression-free survival (PFS) compared to docetaxel, the current standard of care chemotherapy, in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) treated with at least one prior therapy. […]

July 6, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 6 Jul 2023

£100M LifeArc program aims to help people living with rare diseases

LifeArc, a self-funded, non-profit medical research organization and charity, is launching a new program to invest more than £100 million ($127.2 million) by 2030 to deliver new breakthroughs to improve the lives of people living with a rare disease. The Rare Disease Translational Challenge will bring together researchers in rare disease with LifeArc to get […]

July 6, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 5 Jul 2023

Narcolepsy drug gets Chinese approval

RareStone Group, a rare disease-focused company aiming to establish the first rare disease ecosystem in China, has announced that the Chinese National Medical Products Administration (NMPA) has approved pitolisant (Wakix) for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy. In China, pitolisant is the first approved innovative drug for […]

July 5, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 4 Jul 2023

Innovent and IASO Bio obtain approval for CAR-T multiple myeloma treatment

Innovent Biologics, Inc. and IASO Biotechnology have announced that China’s National Medical Products Administration (NMPA) has approved the New Drug Application (NDA) for FUCASO (Equecabtagene Autoleucel). FUCASO is the first fully-human BCMA-directed chimeric antigen receptor (CAR) T-cell therapy for adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least three prior […]

July 4, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 4 Jul 2023

Camena Bioscience raises $10M for DNA synthesis platform

Camena Bioscience, a synthetic biology company providing genes to the pharmaceutical and biotechnology industries, has closed a $10m Series A financing round, led by Mercia. The new funding will be used to scale operations and continue development of its DNA synthesis platform, gSynth. Camena Bioscience is the first company to offer the enzyme-based DNA synthesis […]

July 4, 2023 - 2 minutesmins - By Jim Cornall

Cristina Müller heads the Nuclide Chemistry research group at the Paul Scherrer Institute.

News and Trends 4 Jul 2023

New drug helps prostate cancer patients

Researchers at the Paul Scherrer Institute (PSI) in Switzerland have developed a new drug that could increase the survival chances of patients with metastatic prostate cancer. The drug is now being tested on patients in the PROGNOSTICS project. A research consortium consisting of the PSI, the University Hospital Basel and ETH Zurich is receiving CHF […]

July 4, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 4 Jul 2023

Exeliom Biosciences closes €24M financing for lead candidate

Exeliom Biosciences has completed a €24 million ($26 million) Series A to progress the clinical development of its therapeutic pipeline. This includes several clinical trials of EXL01, a novel immunotherapy with applications in cancer and in infectious diseases. This follows on from the initial closing of €7 million ($7.6 million) in 2018, a first extension […]

July 4, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 3 Jul 2023

New osteoarthritis treatment for horses could work for humans

For the first time, an intervention that seems to slow down osteoarthritis (OA) progression has been presented. In a clinical study from the Swedish University of Agricultural Sciences and the University of Gothenburg, OA horses that received a novel drug treatment became completely free from lameness, with a simultaneous impediment of the joint tissue degradation. […]

July 3, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 30 Jun 2023

Scientists design new enzyme using Antarctic bacteria and computer calculations

For the first time, researchers have succeeded in predicting how to change the optimum temperature of an enzyme using large computer calculations. A cold-adapted enzyme from an Antarctic bacterium was used as the basis. The study is to be published in the journal Science Advances and is a collaboration between researchers at Uppsala University in […]

June 30, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 30 Jun 2023

FDA approves BioMarin gene therapy for hemophilia A

BioMarin Pharmaceutical Inc. has announced that the United States Food and Drug Administration (FDA) has approved ROCTAVIAN (valoctocogene roxaparvovec-rvox) gene therapy for the treatment of adults with severe hemophilia A (congenital factor VIII (FVIII) deficiency with FVIII activity < 1 IU/dL) without antibodies to adeno-associated virus serotype 5 (AAV5) detected by an FDA-approved test. The […]

June 30, 2023 - 5 minutesmins - By Jim Cornall

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

LIfT produces neutrophil-based cell therapy from iPSCs

Positive data from Sensorion hearing loss study

AstraZeneca non-small cell lung cancer drug meets primary endpoint

£100M LifeArc program aims to help people living with rare diseases

Narcolepsy drug gets Chinese approval

Innovent and IASO Bio obtain approval for CAR-T multiple myeloma treatment

Camena Bioscience raises $10M for DNA synthesis platform

New drug helps prostate cancer patients

Exeliom Biosciences closes €24M financing for lead candidate

New osteoarthritis treatment for horses could work for humans

Scientists design new enzyme using Antarctic bacteria and computer calculations

FDA approves BioMarin gene therapy for hemophilia A

Subscribe to our newsletter to get the latest biotech news!